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https://doi.org/10.1016/j.xcrm.2020.100185SUMMARYBCG vaccination can strengthen protection against pathogens through the induction of epigenetic andmeta-
bolic reprogramming of innate immune cells, a process called trained immunity. We and others recently
demonstrated that mucosal or intravenous BCG better protects rhesus macaques from Mycobacterium
tuberculosis infection and TB disease than standard intradermal vaccination, correlating with local adaptive
immune signatures. In line with prior mouse data, here, we show in rhesus macaques that intravenous BCG
enhances innate cytokine production associated with changes in H3K27 acetylation typical of trained immu-
nity. Alternative delivery of BCG does not alter the cytokine production of unfractionated bronchial lavage
cells. However, mucosal but not intradermal vaccination, either with BCG or the M. tuberculosis-derived
candidate MTBVAC, enhances innate cytokine production by blood- and bone marrow-derived monocytes
associated with metabolic rewiring, typical of trained immunity. These results provide support to strategies
for improving TB vaccination and, more broadly, modulating innate immunity via mucosal surfaces.INTRODUCTION
Canonical vaccinology aims at the induction of long-lived adap-
tive memory in antigen-specific lymphocyte populations and
T and/or B cells. Innate immunity in vaccinology is primarily
acknowledged in the context of vaccine formulation and the
quintessential innate immune activation of professional
antigen-presenting cells (APCs) that will prime and skew the
adaptive response of lymphocytes.1 For years, innate immune
responses and myeloid monocyte/macrophage function were
considered constant and invariable over time, but it is nowwidely
recognized that also innate immune cells can adapt and display
memory-like phenotypes. This innate immune ‘‘memory’’ is typi-
cally referred to as trained immunity.2
Induction of trained immunity is defined by a functional adap-
tation of innate immunity after a primary insult resulting in a more
effective response upon a ‘‘secondary’’ encounter with an unre-
lated pathogen.2 It is characterized by increased cytokine and/or
chemokine production,3 metabolic rewiring,4 and epigenetic re-Cell Repo
This is an open access article under the CC BY-Nprogramming of innate immune cells.5 Trained immunity is not
associated with the characteristic immune receptor gene rear-
rangements that are associated with the antigen specificity of
adaptive memory, but rather is driven by the epigenetic control
of specific immune gene clusters resulting in the upregulation
of particular pro-inflammatory cytokines.6 An epigenetic mark
in particular associated with trained immunity in monocytes,
and used in the present study, is the acetylation of histone 3 at
the position of lysine 27 (H3K27ac).7 Recent work in mice has
shown that Bacillus Calmette-Guérin (BCG)-mediated training
of the myeloid monocyte/macrophage lineage is sustained by
the epigenetic reprogramming of hematopoietic stem cells
(HSCs), the myeloid precursors in bone marrow (BM).8
Mycobacterium bovis-derived BCG, currently the only avail-
able vaccine to fight tuberculosis (TB),9 is the prototypical bio-
logical agent for which trained immunity has been demonstrated.
Trained immunity has been linked to the beneficial heterologous
off-target effect of infant BCG vaccination, which from epidemi-




OPEN ACCESSmortality from causes other than TB.10–13 Emerging evidence
supports the hypothesis that not only adaptive memory but
also the memory-like plasticity in innate immunity positively con-
tributes to immune protection against and early clearance of
M. tuberculosis (Mtb) infection.14,15 Although not established
as features of innate training, a comparative analysis in macaque
species suggests that markers of innate immunity and myeloid
monocyte function are associated with differential TB disease
susceptibility.16
Despite the widespread use of live attenuated BCG as prophy-
laxis against TB, it is only partially efficacious and by and large
fails to protect adolescents and adults from the infectious
pulmonary manifestation of Mtb infection.17 Thus, TB continues
to be a major threat to global human health, and a better
vaccination strategy is urgently needed to relieve the burden of
TB.18,19 While intradermal injection is the standard route for
BCG vaccination, historical data in rhesusmacaques have shown
that mucosal or intravenous administration provided superior sig-
nals of protection against experimental infection.20 We have
recently demonstrated that pulmonary mucosal BCG vaccination
reduced disease in a cohort of rhesus macaques in which intra-
dermal BCG failed to show any protective effect.21 In a subse-
quent study, exploiting repeated limiting dose (RLD) rather than
single dose Mtb challenge, we have shown that mucosal but
not intradermal BCG provides signals of prevention of infection.22
Most recently, Darrah and colleagues23 have corroborated the su-
perior protective capacity of BCGwhen given intravenously. Both
studies did not identify an immune biomarker in the blood that
correlated with the protective efficacy of either mucosal or intra-
venous BCG vaccination. Locally, however, antigen-specific
interleukin-17A-positive (IL-17A+) polyfunctional T helper (Th)
cells and IL-10 secretion in the airways did correlate with protec-
tion,22 and the article by Darrah et al.23 suggests that tissue-resi-
dent lymphocytes may be pivotal in conferring protection. While
from these non-human primate (NHP) studies unconventional
administration of BCG appears to be a most interesting lead for
improving our current TB prophylaxis, it remains to be estab-
lished, however, if and how alternative routing of BCG affects
innate and trained immunity.
Various candidate TB vaccines, ranging from subunit formula-
tions to live attenuated and recombinant mycobacteria, are at
various stages of clinical testing in the current vaccine-develop-
ment pipeline (www.tbvi.eu/what-we-do/pipeline-of-vaccines/).
Of the live attenuated candidates, MTBVAC is unique in that it
is derived from a clinical isolate of Mtb (Mt103) rather than
from M. bovis (which is the parental strain of BCG and recombi-
nant BCG candidates).24,25 MTBVAC is attenuated by deletion of
the phoP and the fadD26 gene. Thereby, the expression of viru-
lence factors is critically disrupted, while an intrinsically broader
antigen repertoire in comparison to BCG is preserved.26 Aguilo
et al.27 demonstrated that the expression of ESAT6 and CFP10
by MTBVAC is key to its protective capacity in a mouse models
of TB. MTBVAC has shown preclinical efficacy better than BCG
in animal models.24,27 MTBVAC vaccination protects rhesus
macaques against aerosol challenge with Mtb and induces im-
mune signatures analogous to those observed in clinical
studies.28 It has tested safe and immunogenic in adult and infant
human populations so far.9,29 Similar to BCG,MTBVAC is able to2 Cell Reports Medicine 2, 100185, January 19, 2021generate trained immunity through the induction of glycolysis
and glutaminolysis, and the accumulation of histone methylation
marks at the promoters of proinflammatory genes. Recently,
Tarancón et al.30 showed that MTBVAC-induced heterologous
protection against a lethal challenge with Streptococcus pneu-
moniae in an experimental murine model of pneumonia.
In the present study, we sought to investigate the impact of
live attenuated mycobacterial vaccination via the respiratory
mucosa on trained innate immunity in NHPs. To this end,
we followed a 2 3 2 factorial design strategy for an immuno-
genicity analysis in adult rhesus macaques, vaccinating ani-
mals by intradermal injection or by endobronchial instillation
either with BCG or with MTBVAC. We confirmed the distinc-
tive adaptive response profile in the airways upon pulmonary
mucosal delivery of BCG and MTBVAC, and analyzed the
production of innate and adaptive cytokines after in vitro
stimulation of cells obtained from lung, blood, and BM. We
piloted the induction of trained immunity after intravenous
BCG injection, demonstrating the increased acquisition of
H3K27ac marks and resulting in prominent increased cyto-
kine production after heterologous stimulation in monocytes
isolated from blood and BM. We subsequently demonstrated
that respiratory mucosal administration of live attenuated
mycobacterial vaccines more efficiently induced trained im-
munity in blood and BM monocytes, compared to intradermal
immunization, whereby MTBVAC was equally potent as BCG.
Our findings underpin the innate immune stimulatory potential
of the candidate TB vaccine, MTBVAC. For live attenuated
mycobacterial vaccines in general, they suggest the enhance-
ment of innate immune training via respiratory mucosal vac-
cine administration.
RESULTS
In the present study, we set out to investigate whether
mucosal administration of live attenuated TB vaccines in rhe-
sus macaques could modulate innate immune responses and
induce trained immunity. To this end, we selected healthy,
purpose-bred adult rhesus macaques (Macaca mulatta),
both males and females, and stratified them into comparable
groups of 6 animals each (Table S1). By random assignment
in a 2 3 2 factorial design strategy, these groups received
either a standard human dose of BCG or the equivalent
dose of the live attenuated candidate vaccine, MTBVAC, by
intradermal injection (BCG.id; MTBVAC.id) or by endobron-
chial instillation into the lower right lung lobe (BCG.muc;
MTBVAC.muc). For the assessment of adaptive and/or innate
immunity, relevant samples were collected before and after
vaccination from the airways by bronchoalveolar lavage
(BAL), from the blood by venipuncture, and from the BM by
needle aspiration. Before analyzing the intradermal and
mucosal vaccination groups, and since it had been reported
as an effective research strategy for measuring trained immu-
nity in mice,8 a separate group of 3 rhesus macaques were
vaccinated by intravenous BCG injection (BCG.iv) to pilot-
trained immunity profiling of monocytes (2 weeks after vacci-
nation). A schematic diagram of vaccination and sampling
over time is displayed in Figure 1.
Figure 1. Schematic representation of the
timeline of vaccination in the different vacci-
nation strategies
The BCG.iv group (n = 3) was analyzed at weeks1
and 2. The groups that were immunized with BCG.id
(n = 6), BCG.muc (n = 6), MTBVAC.id (n = 6), and
MTBVAC.muc (n = 6) were analyzed at weeks 1
and 8. Only frommucosally vaccinated animals BAL
was collected from the right lung as well as the left
lung. See also Table S1.
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OPEN ACCESSBCG andMTBVAC are immunogenic and both display an
adaptive immune profile specific to the route of
vaccination
To confirm the efficiency of vaccination, we performed a specific
interferon-g (IFN-g) enzyme-linked immunosorbent spot
(ELISpot) assay after in vitro recall stimulation of peripheral blood
mononuclear cells (PBMCs) with the protein-purified derivative
(PPD) of Mtb (or culture medium as a negative control). For
both BCG andMTBVAC and by either route of delivery, we found
an increase in antigen-specific IFN-g release after primary vacci-
nation. In line with previous observations,21,22 the vaccine-
induced IFN-g response was higher after intradermal over
mucosal BCG delivery, and a comparable response pattern
was observed with MTBVAC (Figures 2A and 2B). When stimu-
lating with a recombinant fusion protein of ESAT6 and CFP10,
two antigens encoded in the region of deletion (RD)1 that is
absent from M. bovis BCG but present in MTBVAC, positive
IFN-g release signals were obtained only from MTBVAC-vacci-
nated animals, as expected (Figure 2C).
To further confirm the adaptive response profile that we regis-
tered previously after pulmonary mucosal BCG as a correlate of
the prevention of Mtb infection, we assessed the cytokine pro-
duction profile of CD4+ T lymphocytes from the airways by
flow cytometry22 after ex vivo stimulation with PPD. As expected,
we detected the most prominent levels of polyfunctional Th17
cells (producing IL-17A, IFN-g, tumor necrosis factor a
[TNF-a], and IL-2) in BALs that were collected 8 weeks after
primary vaccination with BCG via the pulmonary mucosal rather
than the intradermal route (Figure 2D). Mtb-derived MTBVAC
was found to induce a similar response pattern and to be at least
as potent as BCG. Regardless of the vaccine, significant
numbers of polyfunctional Th17 cells were also recovered from
the lower left lung lobe (i.e., opposite of the site targeted by en-
dobronchial immunization), suggesting that the polyfunctional
Th17 response is not contained to the site of vaccination but dis-
seminates locally.
Establishing trained immunity in monocytes after
intravenous immunization with BCG
To evaluate the induction of trained immunity after standard in-
tradermal versus mucosal vaccination with live attenuated TB
vaccines, we established the feasibility of the detection of
trained immunity in the nonhuman primate model. For this, we
immunized three animals with BCG intravenously, a protocol
that was successfully explored in mice by Kaufmann et al.8 To
minimize the interference of a developing adaptive immune
responsewhile still being able to detect robust innate immune re-
sponses, we took samples from different compartments at week2 after vaccination. Next to the analysis of BAL cells from the
lung, we performed a more selective analysis of myeloid
CD14+ monocytes purified from fresh PBMCs (PBMC.mo) and
BM (BM.mo), the prototypic cells in which the trained immunity
phenotype has been described. CD14+ monocyte populations
were obtained by positive selection (using magnetic bead-cell
sorting) and typically reached a purity of ±90% (Figure S1).
Both unfractionated BAL cells and enriched monocytes from
blood and BM were subsequently analyzed for signals of trained
immunity after in vitro restimulation with Mtb-derived whole-cell
lysate (WCL) or the heterologous Escherichia coli derived Toll-
like receptor (TLR)-4 agonist lipopolysaccharide (LPS). After 24
h, supernatants were harvested, frozen, and analyzed later for
cytokine production, indicative of trained innate immunity,
including TNF-a, IL-6, and IL-1b.
After intravenous BCG vaccination, we found marginal sup-
pression of cytokine secretion, if any effect at all, after comparing
Mtb or LPS stimulation of BAL (Figures 3A and 3B). Stimulation of
PBMC.mo and BM.mo with Mtb revealed markedly increased
levels of TNF-a 2weeks after BCG.iv (Figure 3A), but no apparent
modulation of IL-6 and IL-1b secretion levels. However, heterol-
ogous stimulation with LPS demonstrated prominent increased
production of all three cytokines by both monocytes from the
blood and BM (with the exception of a single animal with high
baseline levels in BM.mo; Figure 3B, PBMC.mo and BM.mo).
Metabolic rewiring, specifically a switch from oxidative phos-
phorylation to glycolysis under aerobic conditions,4 has been
described as an initiating event underlying trained immunity.
Therefore, we measured lactate, a metabolite of glycolysis,
levels in the supernatants of stimulated blood- and BM-derived
monocytes as a surrogate marker of metabolic rewiring, and
thus trained immunity. Lactate production was observed for
2 of 3 LPS-stimulated BM.mo, but undetectable for PBMC.mo
(Figure 3C).
Ultimately, we determined whether BCG.iv vaccination re-
sulted in epigenetic reprogramming, another hallmark of trained
innate immunity, in blood-derived monocytes (PBMC.mo).
Therefore, we examined the dynamics of histone modification
H3K27ac (an epigenetic mark associated with active chromatin
in the context of trained immunity7) after BCG.iv by chromatin
immune precipitation, followed by high-throughput sequencing
(chromatin immunoprecipitation sequencing [ChIP-seq]) to
assess the changes associated with BCG.iv vaccination.
H3K27ac changes were detected at many loci (Figures 3D–3F).
In total, we detected 792 regions increased and 646 regions
decreased in H3K27ac (Figure 3D). While the regions showing
increased acetylation were associated with genes related to
the cell cycle, signaling, and activation of the immune response,Cell Reports Medicine 2, 100185, January 19, 2021 3
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Figure 2. Mucosal vaccination establishes a unique local adaptive signature defined by polyfunctional Th17 cells
(A–C) Individual IFN-g ELISpot responses after in vitro recall stimulation of PBMCs against PPD (A) before vaccination or (B) 8 weeks after vaccination or with (C)
ESAT6-CFP10 8weeks after vaccination. Horizontal lines in bars indicate groupmedians; n = 6 animals/group. ANOVA adjusted formultiple comparisons; Dunn’s
multiple comparison test.
(D) The percentages of polyfunctional IL-17A+ PPD-specific CD4+ T cells (also producing IFN-g, TNF-a, and IL-2) were determined by flow cytometric analysis of
BAL cells before (PRE) and 8 weeks after intradermal (.id) or mucosal (.muc) vaccination. Cells were typically collected from the lower right lung lobe (R); targeted
for vaccination) and for mucosally vaccinated animals also from the left lung (L) to establish dissemination of the immune response. The data are presented as
medium control corrected (cc); n = 6 animals/group; Wilcoxon matched-pairs signed rank test. ULD, upper limit of detection; LLD, lower limit of detection.
See also Figure S7.
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OPEN ACCESSregions decreased in acetylation were associated with genes
involved in cellular differentiation (Figure 3E). Examples for
both an active region, IFN regulatory factor 3 (IRF3), and sup-
pressed region, syndecan 2 (SDC2) are given (Figure 3F). These
data are in line with vaccination-induced changes in the acety-
lome and the cellular program related to the induction of trained
immunity.
Pro-inflammatory cytokine production after stimulation
of BAL cells with Mtb or LPS
We then sought to compare the induction of trained immunity af-
ter standard intradermal versusmucosal vaccination with the live
attenuated TB vaccines BCG and MTBVAC. We analyzed cyto-
kine/chemokine production in BAL cells after ex vivo stimulation
with homologous Mtb WCL or heterologous LPS. Using a
tailored multiplex kit for cytokine and chemokine measurement,4 Cell Reports Medicine 2, 100185, January 19, 2021we assessed the production of molecules that have previously
been associated with lymphocyte activation and function
(IFN-g, IL-2, IL-17A), inflammation, leukocyte differentiation,
migration, and/or with trained immunity (TNF-a, IL-6, IL-1b,
granulocyte-macrophage-colony-stimulating factor [GM-CSF],
macrophage inflammatory protein 1a [MIP-1a; CCL3], and IFN-
g-induced protein 10 [IP-10; CXCL10]).3,11,31 In line with the
flow cytometric detection of polyfunctional Th17 cells, we found
significantly elevated levels of IL-17A, IFN-g, IL-2, and TNF-a
secretion from Mtb WCL-stimulated BAL cells—in particular
after mucosal vaccination with BCG or MTBVAC (Figure 4A). A
significant increase in the secretion of IL-2 and TNF-a (but not
IL-17A and IFN-g) was also measured after intradermal vaccina-
tion. As the response levels of BCG and MTBVAC in this regard
were indistinguishable, we have depicted results and performed
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OPEN ACCESSarms together, per route of administration. The release of pro-in-
flammatory IL-6, after in vitro stimulation with Mtb WCL,
comparing pre- and post-vaccination time points, was rather
heterogeneous. In contrast, IL-1b, GM-CSF, and MIP-1a
(CCL3) secretion was, by trend or with statistical significance,
decreased in mucosally vaccinated animals (Figure 4A). CXCL-
10 (IP-10), however, was markedly and significantly increased
upon Mtb WCL stimulation, regardless of the nature of the vac-
cine or the immunization route.
This cytokine/chemokine secretion profile of BAL cells after
stimulation with a preparation as crude as the WCL ofMtb, con-
taining both protein antigens and (non-protein) innate receptor
ligands, is the net result of adaptive and innate activation of all
subsets that are present in the unfractionated BAL cell popula-
tion. In addition, it must be noted that the relative abundance
of immune cell subsets in BAL is affected by pulmonary mucosal
but not by intradermal BCG vaccination toward a relative in-
crease in T lymphocytes over alveolar macrophage (Figure S2).
To at least circumvent the adaptive component of this response
profile and toward the assessment of trained immunity by heter-
ologous innate stimulation, we also stimulated BAL cells with
LPS to measure the ensuing cytokine production capacity.
Upon LPS, and in contrast to Mtb WCL stimulation, IL-17A,
IFN-g, and TNF-a concentrations after vaccination were no
different from what was found at baseline (Figure 4B). Most likely
as a result of the bystander activation of T lymphocytes specif-
ically recruited into the airways after mucosal vaccination, IL-2
release upon LPS stimulation was increased with BAL cells
from mucosally vaccinated animals (Figure 4B), but to a lesser
extent compared to Mtb WCL stimulation (Figure 4A). Also
compared to Mtb WCL stimulation, the vaccination-modulated
GM-CSF secretion of BAL cells was lost with LPS, and that of
CXCL-10 was much lower and heterogeneous (Figure 4B).
LPS-stimulated IL-6 levels were comparably heterogeneous as
with Mtb WCL stimulation. IL-1b and MIP-1a, as with Mtb WCL
stimulation, showed diminished secretion upon the LPS stimula-
tion of BAL cells after vaccination, regardless of the route of vac-
cine delivery (Figure 4B).
This cytokine/chemokine secretion analysis of unfractionated
BAL cells upon heterologous LPS (or homologous Mtb WCL)
stimulation did not reveal a signal of trained immunity in the air-
ways after (mucosal) live attenuated mycobacterial vaccination.
Induction of trained immunity in monocytes after
mucosal vaccination with BCG and MTBVAC
Since BAL cells did not provide a signal indicative of trained im-
munity, we sought to compare the induction of trained immunityFigure 3. Trained immunity after intravenous BCG vaccination
(A and B) Freshly isolated BAL cells (from the right lung) and monocytes from bloo
whole-cell lysate (25 mg/mL) or (B) LPS (0.1 mg/mL) before and 2 weeks after in
corrected.
(C) Lactate production as an indicator of metabolic rewiring was measured in 24-h
or BM (BM.mo). See also Figure S1.
(D) Heatmap of H3K27ac reads (red) over BCG-specific peaks. The intensity ove
(E) The top GO pathways associated with the nearest genes to dynamic H3K27a
(F) H3K27ac dynamics at interferon regulatory factor 3 (IRF3) and syndecan 2 (SD
and values can be found at GEO: GSE159046.
6 Cell Reports Medicine 2, 100185, January 19, 2021through ex vivo heterologous LPS stimulation of blood- and
BM-derived monocytes, as was shown for BCG.iv between in-
tradermal and mucosal immunized animals, with live attenuated
BCG or MTBVAC. To demonstrate that the cytokine production
is due to ex vivo heterologous LPS stimulation and exclude the
possibility of continued innate activation by the (persisting) vac-
cine, unstimulated medium controls were included that showed
minimal to no production of cytokines (Figure S3).
While T cell-derived cytokines IL-17A, IFN-g, and IL-2were not
detected upon monocyte stimulation (not shown), the enhance-
ment of LPS-stimulated secretion of TNF-a, IL-6, and IL-1b was
evident in some but not all animals that were vaccinated by intra-
dermal injection (Figure 5A). Specifically, 4 of 11 animals (2 from
each of the BCG- and the MTBVAC-vaccinated groups) showed
elevated TNF-a production with an effect size (independent
of baseline production) of >2-fold increase after BCG.id/
MTBVAC.id (Figure 5B; due to a technical error, we missed the
baseline values of a single animal of the MTBVAC.id group).
Similarly, 4 of 11 showed the opposite effect of decreased
TNF-a levels after BCG.id/MTBVAC.id, while 3 of 11 showed
no considerable modulation of LPS-stimulated TNF-a after intra-
dermal vaccination (Figure 5B). Of note, Mtb-derived MTBVAC
appeared equally as potent as BCG in the induction of trained
immunity in PBMC.mo (Figure S4A). Notably, the secretion levels
of pro-inflammatory IL-6 and IL-1b showed a pattern similar to
that of TNF-a. The ratio of the production for the 3 signature cy-
tokines (TNF-a, IL-6, and IL-1b) did not deviate over a period of
8 weeks in a cohort of unvaccinated animals (Figure S4C).
In contrast to intradermal BCG/MTBVAC vaccination, the
mucosal delivery of these live attenuated vaccines resulted in a
robust and significant enhancement of TNF-a, IL-6, and IL-1b
production after LPS stimulation in 10 of 12 animals (Figures
5A and 5B; 5 animals from the BCG and theMTBVAC vaccinated
group each). Themedian effect size was 15.1, 6.2, and 5.9 for the
fold increase in TNF-a, IL-6, and IL-1b production, respectively
(Figure 5B). For GM-CSF and MIP-1a, 2 cytokines that have
been associated with trained immunity, a similar pattern of
enhanced secretion after prior mucosal rather than intradermal
vaccination was obtained (Figures 5A and 5B). This enhance-
ment, however, was less prominent than for TNF-a, IL-6, and
IL-1b, with a median fold-increase of GM-CSF and MIP-1a after
BCG.muc/MTBVAC.muc of 2.1 and 2.9, respectively (Figure 5B).
CXCL-10 was not detected from these monocyte stimulation
analyses (Figure 5A). Comparing BCG to MTBVAC within each
route of delivery (id versus muc) strategy demonstrated that
both vaccines were equally potent in mediating trained immunity
(Figure S5A). We explored the mycobactericidal activity withd (PBMC.mo) and bone marrow (BM.mo) were stimulated for 24 h with (A)Mtb
travenous vaccination with BCG. The data are presented as medium control
supernatant from LPS-stimulated monocytes purified from blood (PBMC.mo)
r the center of the peak ± 12 kb is depicted.
c, with adjusted p values.
C2) locus for PBMC.mo pre- and post-vaccination. The complete list of genes
A
B
(legend on next page)






Figure 5. Trained immunity after mucosal vaccination in peripheral blood monocytes
Cytokine production was measured after 24 h of stimulation with LPS (0.1 mg/mL).
(A) Paired display of cytokine levels before and 8 weeks after vaccination. The data are presented as medium control corrected (mcc; BCG in circles; MTBVAC in
triangles). Statistical significance was calculated by Wilcoxon’s non-parametric paired analysis test (n = 12 animals/group; PRE versus 8 weeks post-vacci-
nation). p values are indicated at the top of each graph.
(B) Median fold increase in cytokine production is indicated in italics; significant p < 0.05 is indicated in bold; n = 12 animals/group; Wilcoxon signed rank test.
See also Figures S1, S3, S4, S5, and S6.
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OPEN ACCESSPBMC.mo isolated from residual frozen PBMCs, but within the
limits of our efforts, we did not detect mycobactericidal activity
by trained monocytes (Figure S6).Figure 4. Cytokine production by BAL cells
Freshly isolated BAL cells were stimulated (A) withMtbwhole cell lysate or (B) LPS
(with either BCG, in circles, or MTBVAC, in triangles). Cells were typically collect
mucosally vaccinated animals also from the left lung (L), to establish dissemination
(mcc); n = 12 animals/group; Wilcoxon matched-pairs signed rank test. p values
8 Cell Reports Medicine 2, 100185, January 19, 2021Next to PBMC.mo, we addressed the LPS-stimulated cyto-
kine/chemokine secretion potential of BM-derived CD14+
monocytes (BM.mo) before and after BCG or MTBVAC, before (PRE) and 8 weeks after intradermal (.id) or mucosal (.muc) vaccination
ed from the lower right lung lobe (R), the lobe targeted by vaccination, and for
of the immune response. The data are presented asmedium control corrected
are indicated at the top of each graph. See also Figure S2.
A
B
Figure 6. Trained immunity after mucosal vaccination in BM monocytes
Cytokine production was measured after 24 h of stimulation with LPS (0.1 mg/mL).
(A) Paired display of cytokine levels before and 8 weeks after vaccination. The data are presented as medium control corrected (mcc; BCG in circles; MTBVAC in
triangles). Statistical significance was calculated by Wilcoxon’s non-parametric paired analysis test (n = 12 animals/group; PRE versus 8 weeks post-vacci-
nation). p values are indicated at the top of each graph.
(B) Median fold increase in cytokine production is indicated in italics; significant p < 0.05 is indicated in bold; n = 12 animals/group; Wilcoxon signed rank test.
See also Figures S1, S4, and S6.
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OPEN ACCESSvaccination. Similar to what was observed for PBMC.mo, af-
ter intradermal BCG/MTBVAC delivery, trained immunity by
enhanced TNF-a, IL-6, and IL-1b secretion was apparent in
only a subset of animals, whereas in others there was no ef-
fect or an inverse effect of yielding reduced innate cytokine
release after vaccination (Figures 6A and 6B). Also, in accor-
dance with PBMC.mo profiling, after mucosal BCG/MTBVACdelivery, cytokine production and, in particular the secretion
of TNF-a and IL-1b, was significantly enhanced (Figure 6A).
Again, the proportion of subjects showing trained immunity
signals was higher after mucosal than after intradermal vacci-
nation, although the effect size appeared less prominent than
with PBMC.mo (3.1, 4.1, and 5.0 for TNF-a, IL-6 and IL-1b,
respectively), the median effect size is increased for TNF-aCell Reports Medicine 2, 100185, January 19, 2021 9
A B C Figure 7. Increased lactate production after
mucosal vaccination
(A and B) Lactate production as an indicator of
metabolic rewiring was measured in 24-h superna-
tant from LPS-stimulated monocytes purified (A)
from peripheral blood, or (B) BM. Statistical signifi-
cance between group median values was calcu-
lated byMann-Whitney rank testing and indicated at
the top. The box extends from the 25th to 75th
percentiles while the whiskers go down to the
smallest value and up to the largest.
(C) Median fold increase in lactate production is
indicated in italics; significant p < 0.05 is indicated in
bold; n = 12 animals/group; Wilcoxon signed rank
test.
See also Figure S6.
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OPEN ACCESSand IL-1b in mucosally vaccinated compared to intradermally
vaccinated animals (Figure 6B). In contrast to PBMC.mo anal-
ysis, there was no trained immunity effect apparent by the
secreted amounts of GM-CSF and MIP-1a from BM.mo (Fig-
ures 6A and 6B). Also, for BM.mo, we did not observe a dif-
ference between BCG and MTBVAC in the ability to induce
trained immunity (Figure S4B).
To investigate whether metabolic rewiring occurs after BCG or
MTBVAC vaccination, we measured lactate production in the
conditioned supernatants of LPS-stimulated blood- (PBMC.mo)
and BM- (BM.mo) derived monocytes. When comparing the two
routes of vaccination, the change in lactate production by LPS-
stimulated PMBC.mo is significantly higher after mucosal than
intradermal delivery (Figure 7A; p = 0.020). The increase in
lactate production after mucosal vaccination is nearly significant
(Figure 7C; p = 0.0522). When analyzing BM.mo, this differential
effect of vaccine route on lactate production is less prominent
and not significant (Figure 7B; p = 0.26). Importantly, the change
in the production of hallmark cytokines of trained immunity (TNF-
a, IL-6, and IL-1b) correlated well with the change in lactate pro-
duction (Figure S6), especially after mucosal vaccination with
BCG/MTBVAC (Figure S6B).DISCUSSION
In the present study we investigated the induction of trained
immunity in myeloid leukocytes from adult rhesus macaques
by immunization with live attenuated mycobacterial vaccine via
different administration routes. The results demonstrate the
induction of memory-like trained immunity in immune cells
from NHPs, as determined by epigenetic reprogramming and
enhanced ex vivo cytokine and lactate production upon second-
ary heterologous stimulation. Although we could not reveal a
signal of trained immunity in unfractionated BAL cells after
(mucosal) live attenuatedmycobacterial vaccination, we demon-
strated robust innate immune training in the periphery
(PBMC.mo and BM.mo) for both MTBVAC and BCG, delivered
via the respiratory mucosa as compared to intradermal injection.
Combined with our previous findings of mucosal BCG delivery
conferring an improved reduction of disease and prevention of
Mtb infection,21,22 this study provides strong rationale for the10 Cell Reports Medicine 2, 100185, January 19, 2021further investigation of innate immune training and its underlying
mechanisms in relation to TB immunity and vaccine efficacy.
The scope of this study was limited to immunogenicity ana-
lyses only. Therefore, the formal correlation between individual
signatures of trained immunity and protective efficacy of live
attenuated whole-cell vaccination remains to be established.
However, the enhanced secretion of the cytokines, TNF-a, IL-
6, and GM-CSF, observed in the present study, is in accordance
with our previous finding of a significant correlation between the
individual secretion levels for these cytokines after vaccination
and the outcome of experimental RLD challenge with Mtb (see
the supplemental data in Dijkman et al.22).
In line with what has been reported for intravenous BCG in
mice,8 we demonstrated that upon intravenous BCG vaccination
in NHPs, the effective induction of trained immunity in blood-
derived monocytes, associated with epigenetic reprogramming,
could be observed. It is tempting to speculate that the superior
protection of BCG when delivered intravenously, as demon-
strated by Darrah et al.,23 may in part be the result of innate im-
mune training, although these investigators did not find innate
immune activation in PBMCs to support this speculation.
Furthermore, beyond the prevention of infection signals from
the aforementioned NHP studies, it is also interesting to consider
trained immunity as a relevant mechanism in light of BCG revac-
cination’s providing a signal of early clearance by the prevention
of (sustained) Mtb infection in humans.32,33
Beyond these implications from prior observations on protec-
tive TB immunity, the present study emphasizes that innate cyto-
kine secretion by peripheral blood monocytes, upon secondary
heterologous stimulation with LPS, is positively modulated by
live attenuated whole-cell vaccination. Next to TNF-a, IL-6,
and IL-1b as the classical signature cytokines of trained immu-
nity, GM-CSF and MIP-1a (CCL-3) also appeared as innate
immune signals in rhesus macaques linked to trained immunity
by BCG or MTBVAC vaccination. Trained immunity has been
functionally associated with mycobacterial growth inhibition in
human monocytes.31 Within the limits of our efforts, we did not
detect mycobactericidal activity by the trained monocytes. It
must be noted, however, that improved cytokine responses by
monocytes can have important anti-mycobacterial effects inde-
pendent of monocytes themselves, such as activation of lym-
phocytes, lung macrophages, and natural killer (NK) cells.
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correlates such as the induction of enhanced levels of anti-
gen-specific polyfunctional Th17 cells in the airways after
mucosal administration of live attenuated BCG and
MTBVAC. Extended analysis of adaptive immune responses
after vaccination revealed that local T cells expressed high
levels of mucosal homing and tissue-residency markers
that were not found after Mtb infection. Moreover, local an-
tibodies bound to Mtb, mediating enhanced pathogen
uptake. These data are presented in the accompanying
paper by Dijkman et al.34 In addition, the respective innate
cytokine responses from peripheral blood cell populations
may provide useful correlates and biomarkers of vaccine-
induced protection against TB.
The ultimate longevity of trained immunity after vaccination
remains to be established and is likely to be affected by envi-
ronmental exposure or endogenous microbial cues, but it is
clear that the phenotype of trained immunity exceeds the life-
span of the myeloid monocytes by which we determine the
training effect. Several mechanisms have been proposed to
explain HSC activation in the context of infection or vaccina-
tion.32 Kaufmann and colleagues8 have provided a plausible
explanation for this paradox by showing that in mice (intra-
venous) BCG vaccination modulates gene expression and
innate response profiles of HSC, the precursors of the
myeloid monocyte/macrophage lineage in the BM, by epige-
netic reprogramming.8 These findings were extended by
Cirovic et al.,35 who showed the induction of trained HSC
in human after standard intradermal vaccination with BCG.
It is suggested that the trained phenotype gained by the
HSC is passed along to the CD14+ monocytic lineage. At
this point we can only speculate that similar mechanisms
may apply to mucosal BCG vaccination. The current study
does show that innate training as observed in peripheral
blood monocytes is also captured in monocytes purified
from BM. The enhanced lactate production suggests meta-
bolic reprogramming of myeloid monocytes after prior vacci-
nation with BCG or MTBVAC, and in particular after the
mucosal delivery of these vaccines. This may be indicative
of host response modulation associated with long-term im-
mune training. The epigenetic reprogramming observed after
intravenous BCG supports the notion that this modulation
may also underlie the robust increased production of cyto-
kines after mucosal vaccination, but that still needs to be
formally proven.
This study linksmucosal vaccination via the airways to the sys-
temic induction of trained immunity in myeloid cells, but when
analyzing cytokine and chemokine release upon (heterologous)
innate stimulation of BAL cells, we did not observe trained
immunity locally. On the contrary, LPS stimulation of the unfrac-
tionated cell population from lung washes after live attenuated
mycobacterial whole-cell vaccination, and regardless of vacci-
nation route, did reveal significant suppression of IL-1b secretion
in particular, which suggests anti-inflammatory regulation. Such
anti-inflammatory training or innate tolerance response, in
general, may help to preserve local pulmonary homeostasis in
the face of constant environmental exposure to airborne micro-
bial agents.36,37 However, in mice, alveolar macrophages canrender a memory-like phenotype with a pro-inflammatory gene
signature and increased glycolytic metabolism through respira-
tory viral infection and T cell help.38 The functional plasticity of
alveolar macrophages and newly recruited myeloid cells in the
airways as well as tissue-resident macrophages with regard to
trained immunity after TB vaccination and prevention of TB infec-
tion and disease will also require future investigation.
Trained immunity has been proposed to explain epidemiolog-
ical observations that BCG-vaccinated individuals show a broad
reduction of unrelated respiratory infectious disease, compared
to unvaccinated individuals.10 While the heterologous beneficial
effect of BCG is clinically relevant, the recently suggested impact
of elevated innate immunity on natural resistance to and early
clearance ofMtb infection provides further support for including
trained immunity in TB vaccine research and development stra-
tegies.14,15,32,33,39 In this regard, we should realize that, as much
as trained immunity by BCGmay have an impact on subsequent
Mtb encounters, trained immune status at the time of vaccination
may also have an impact on the live attenuated vaccine, its
persistence, and its efficacy. It is noteworthy that not all of the
animals in this study displayed trained immunity upon exposure
to BCG or MTBVAC. Actually, after vaccination via the standard
route of intradermal injection, an equally large proportion of
animals showed the opposite effect of trained immunity (i.e.,
innate tolerance) by displaying reduced rather than enhanced
innate cytokine release to secondary LPS stimulation. Correla-
tion studies will be needed to shed further light on this matter,
but it is tempting to speculate that the status of innate respon-
siveness before vaccination will relate to the variable efficacy
of BCG in the clinic as much as it is observed in standardized
NHP studies using different cohorts of outbred rhesus
macaques.21 In addition, there may be a relevant impact of
exposure to non-tuberculous mycobacteria (NTM) through
innate immune modulation exerting a possibly negative effect
on BCG efficacy, either by masking or by blocking protection
by BCG (re)vaccination.17,40–44
In conclusion, the induction of trained innate immunity as
it occurs in humans is recapitulated in rhesus macaques by
live attenuated TB vaccination using either BCG or the Mtb-
derived candidate vaccine MTBVAC. Moreover, mucosal im-
munization in this regard is more effective and yields more
trained responders than conventional intradermal delivery.
Since mucosal immunization with BCG in rhesus also confers
better protection against TB infection and disease, future
research efforts will address whether trained innate immunity
is a correlate of vaccine-induced protection that can be regis-
tered by PBMCs and/or monocyte response analysis. In a
broader perspective, these findings provide support for inves-
tigating and advancing immunomodulatory treatments based
on trained innate immunity against human immune disorders
via mucosal surfaces.
Limitations of study
The scope of the present study was limited to immunogenicity
analyses since we demonstrated earlier that mucosal vaccina-
tion with BCG results in better protection against TB than stan-
dard intradermal vaccination.22 Therefore, the formal correlation
between individual immune signatures of trained immunity andCell Reports Medicine 2, 100185, January 19, 2021 11
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remains to be established. Although studies in mice identified
alveolar macrophages to be sensitive for the induction of trained
immunity after a respiratory viral infection,38 mediating pro-
tection in the early stages of Mtb infection,45 we did not detect
trained immunity in unfractionated BAL after BCG vaccination in-
dependent of the route of administration. This will be the subject
of future studies. In the present study, we analyzed trained
immunity in isolated monocytes from blood and BM as the pro-
totypical cell population in which trained immunity can be estab-
lished and did not explore trained immunity in unfractionated
blood. Therefore, heterologous stimulation with LPS of isolated
monocytes did not allow us to evaluate interactions with cells
from the adaptive immune arm, such as T cells. Future studies
should delineate the contribution of the adaptive immunity
to trained immunity in unfractionated blood. Although we
confirmed epigenetic reprogramming mediated by altered his-
tone modification after intravenous BCG vaccination, we did
not formally correlate increased cytokine production profiles
with altered histone modification after intradermal and mucosal
vaccination with BCG and MTBVAC.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d RESOURCE AVAILABILITY12B Lead contact
B Materials availability
B Data and code availability
d EXPERIMENTAL MODEL AND SUBJECT DETAILS
B Animals and ethics
B Vaccines and vaccination
d METHOD DETAILS
B Biological sample collection and processing




B Gating strategy for T cells (Figure S7; Related to
Figure 2D)
B BAL cell composition analysis
B Gating strategy for BAL cell composition (Figure S2B)
B Isolation of CD14+ monocytes
B Gating strategy for CD14+ monocytes (Figure S1B)




B Necropsy and post-mortem evaluation
d QUANTIFICATION AND STATISTICAL ANALYSIS
B Data handling ofmeasurements of cytokine production
by Multiplex
B Statistics comparing routes of vaccination, cytokine,
and lactate production
B Statistics epigeneticsCell Reports Medicine 2, 100185, January 19, 2021SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.
xcrm.2020.100185.
ACKNOWLEDGMENTS
We thank the animal and veterinary care teams as well as the pathology team
and clinical lab personnel of BPRC for their outstanding contributions to this
work; F. van Hassel for support with graphics; and Prof. T. Ottenhoff at Leiden
University Medical Centre for providing the ESAT6-CFP10 fusion protein. The
following reagent was obtained through BEI Resources, the NIAID, and the
NIH: M. tuberculosis, Strain Erdman Barcode Library, NR-50781. This NHP
study and the MTBVAC vaccine are linked to the TB vaccine R&D program
of the TuBerculosis Vaccine Initiative (TBVI)-governed TBVAC2020 Con-
sortium, supported by the European Commission under the Horizon 2020 pro-
gramme, grant agreement no. 643381. Extended immune response analyses
were in part supported as a research effort of the TRANSVAC2 Consortium,
also under the Horizon 2020 programme, grant agreement no. 730964.
AUTHOR CONTRIBUTIONS
Conceptualization & Study Design: F.A.W.V., M.P.M.V., and K.D.; Assay Per-
formance, Data Processing, & Analysis: K.D., R.A.W.V., C.C.S., S.O.H., C.B.,
K.G.H., M.P.M.V., M.v.d.S., L.v.E., S.J.C.F.M., and J.D.-A.; Writing – Original
Draft, M.P.M.V. and F.A.W.V.; Writing – Review & Editing, K.D., J.D.-A., J.T.,
E.R., E.P., R.v.C., M.G.N., N.A., and C.M.; Supervision, J.H.A.M., C.H.M.K.,
and F.A.W.V.
DECLARATION OF INTERESTS
E.R., E.P., N.A., and C.M. are co-inventors on a patent on a tuberculosis vac-
cine held by the University of Zaragoza and Biofabri. E.R. and E.P. are em-
ployees of Biofabri. J.T. is an employee of the TuBerculosis Vaccine Initiative
and an advisor to Biofabri. M.G.N. holds a patent on the inhibition of trained
immunity with nanobiologics, and a patent on the stimulation of trained immu-
nity with nanobiologics. M.G.N. is also a scientific founder of Trained Thera-
peutix and Discovery (TTxD). The remaining authors of the Radboud UMC
and the authors from the BPRC declare no competing interests.
Received: April 30, 2020
Revised: October 22, 2020
Accepted: December 15, 2020
Published: January 19, 2021
REFERENCES
1. Kaufmann, S.H.E. (2019). Immunology’s Coming of Age. Front. Immunol.
10, 684.
2. Netea, M.G., Joosten, L.A., Latz, E., Mills, K.H., Natoli, G., Stunnenberg,
H.G., O’Neill, L.A., and Xavier, R.J. (2016). Trained immunity: A program
of innate immune memory in health and disease. Science 352, aaf1098.
3. Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten, L.A., Ifrim, D.C., Saeed,
S., Jacobs, C., van Loenhout, J., de Jong, D., Stunnenberg, H.G., et al.
(2012). Bacille Calmette-Guerin induces NOD2-dependent nonspecific
protection from reinfection via epigenetic reprogramming of monocytes.
Proc. Natl. Acad. Sci. USA 109, 17537–17542.
4. Cheng, S.C., Quintin, J., Cramer, R.A., Shepardson, K.M., Saeed, S., Ku-
mar, V., Giamarellos-Bourboulis, E.J., Martens, J.H., Rao, N.A., Aghajanir-
efah, A., et al. (2014). mTOR- and HIF-1a-mediated aerobic glycolysis as
metabolic basis for trained immunity. Science 345, 1250684.
5. Quintin, J., Saeed, S., Martens, J.H.A., Giamarellos-Bourboulis, E.J., Ifrim,
D.C., Logie, C., Jacobs, L., Jansen, T., Kullberg, B.J., Wijmenga, C., et al.
(2012). Candida albicans infection affords protection against reinfection




OPEN ACCESS6. Netea, M.G., Domı́nguez-Andrés, J., Barreiro, L.B., Chavakis, T., Divan-
gahi, M., Fuchs, E., Joosten, L.A.B., van der Meer, J.W.M., Mhlanga,
M.M., Mulder, W.J.M., et al. (2020). Defining trained immunity and its
role in health and disease. Nat. Rev. Immunol. 20, 375–388.
7. Saeed, S., Quintin, J., Kerstens, H.H., Rao, N.A., Aghajanirefah, A., Matar-
ese, F., Cheng, S.C., Ratter, J., Berentsen, K., van der Ent, M.A., et al.
(2014). Epigenetic programming of monocyte-to-macrophage differentia-
tion and trained innate immunity. Science 345, 1251086.
8. Kaufmann, E., Sanz, J., Dunn, J.L., Khan, N., Mendonça, L.E., Pacis, A.,
Tzelepis, F., Pernet, E., Dumaine, A., Grenier, J.C., et al. (2018). BCG Ed-
ucates Hematopoietic Stem Cells to Generate Protective Innate Immunity
against Tuberculosis. Cell 172, 176–190.e19.
9. Spertini, F., Audran, R., Chakour, R., Karoui, O., Steiner-Monard, V.,
Thierry, A.-C., Mayor, C.E., Rettby, N., Jaton, K., Vallotton, L., et al.
(2015). Safety of human immunisation with a live-attenuated Mycobacte-
rium tuberculosis vaccine: a randomised, double-blind, controlled phase
I trial. Lancet Respir. Med. 3, 953–962.
10. Aaby, P., Roth, A., Ravn, H., Napirna, B.M., Rodrigues, A., Lisse, I.M.,
Stensballe, L., Diness, B.R., Lausch, K.R., Lund, N., et al. (2011). Random-
ized trial of BCG vaccination at birth to low-birth-weight children: benefi-
cial nonspecific effects in the neonatal period? J. Infect. Dis. 204, 245–252.
11. Arts, R.J.W., Moorlag, S.J.C.F.M., Novakovic, B., Li, Y., Wang, S.Y., Oost-
ing, M., Kumar, V., Xavier, R.J., Wijmenga, C., Joosten, L.A.B., et al.
(2018). BCG Vaccination Protects against Experimental Viral Infection in
Humans through the Induction of Cytokines Associated with Trained Im-
munity. Cell Host Microbe 23, 89–100.e5.
12. Higgins, J.P., Soares-Weiser, K., López-López, J.A., Kakourou, A., Chap-
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Antibodies
anti-CD3 – AF700 (clone SP34-2) BD Biosciences Cat#: 557917; RRID: AB_396938
anti-CD4 – PerCP.Cy5.5 (clone L200) BD Biosciences Cat#: 552838; RRID: AB_394488
anti-CD8a – APC-H7 (clone SK1) BD Biosciences Cat#: 641400; RRID: AB_164536
anti-CD14 – BV421 (clone M5E2) BD Biosciences Cat#: 301830; RRID: AB_10959324
anti-CD20 – BV421 (clone 2H7) Biolegend Cat#: 302330; RRID: AB_10965543
anti-CD28 – ECD (clone CD28.2) IOTest Cat#: 6607111; RRID: AB_1575955
anti-CD45RA – PE-CF594 (clone 5H9) BD Biosciences Cat#: 565419; RRID: AB_2739229
anti-CD95 – BV605 (clone DX2) Biolegend Cat#: 305628; RRID: AB_2563825
anti-IL-2 – AF488 (clone MQ1-17H12) Biolegend Cat#: 500314; RRID: AB_493368
anti-IL-17A – PE-Cy7 (clone ebio64DEC17) Biolegend Cat#: 25-7179-42; RRID: AB_11063994
anti-TNF-a – BV650 (clone Mab11) BD Biosciences Cat#: 502938; RRID: AB_2562741
anti-IFN-g – BV711 (clone 4S.B3) BD Biosciences Cat#: 502540; RRID: AB_2563506
anti-CD3ε – FITC (clone SP34) BD Biosciences Cat#: 556611; RRID: AB_396484
anti-CD14 – V450 (T€uk4) Milteny Biotec Cat#: 130-113-152; RRID: AB_10831023
anti-CD20 – BV605 (clone 2H7) Biolegend Cat#: 302334; RRID: AB_2563398
anti-CD45 – BV786 (clone D058-1283) BD Biosciences Cat#: 563861; RRID: AB_2738454
anti-CD3 – BV421 (clone SP34-2) BD Biosciences Cat#: 562877; RRID: AB_2737860
anti-CD14 – BV786 (clone M5E2) BD Biosciences Cat#: 301840; RRID: AB_2563425
anti-CD16 – PE-CY7 (clone 3G8) BD Biosciences Cat#: 560716; RRID: AB_1727433
anti-CD20 – BV605 (clone 2H7) Biolegend Cat#: 302334; RRID: AB_2563398
anti-CD45 – AF700 (clone D058-1283) BD Biosciences Cat#: 561288; RRID: AB_10613813
anti-CD66 – PE (clone TET2) Milteny Biotec Cat#: 130-093-133; RRID: AB_871699
anti-CD206 – PerCP (clone 15-2) BioLegend Cat#: 321122; RRID: AB_10899411
Bvbuffer BioLegend Cat#: 563794; RRID: AB_2869750
VIVID – BV421 Thermofisher Cat#: L34955
Life/Death – eFluor 506 eBioscience Cat#: 65-0866-14
anti-H3K27ac Diagenode Cat#: pab-196-050; RRID: AB_2637079
Bacterial and virus strains
BCG (strain Sofia; 5 3 105 CFU) InterVax Ltd Cat#: not applicable
MTBVAC (M.tub strain; 5 3 105 CFU) Biofabri Cat#: not applicable
Mtb Erdmann BEI Resources Cat#: NR-50781
Chemicals, peptides, and recombinant proteins
Purified Protein Derivate (PPD; M.tub) AJ Vaccines Cat#: 2391
Purified Protein Derivate (PPD; M.bov) Life Technologies NV Cat#: 760060
Purified Protein Derivate (PPD; M.av) Life Technologies NV Cat#: 760065
Whole Cell Lysate (WCL; Mtb HN878) BEI Resources Cat#: NR-14824
Lipopolysaccharide (0111:B4 strain; Ultrapure) Invivogen Cat#: tlrl-3pelps
PMA Sigma-Aldrich Cat#: P8139
Ionomycine Sigma-Aldrich Cat#: I0634
Roswell Park Memorial Institute (RPMI) Life Technologies NV Cat#: 52400041
LymphoprepTM Axis-Shield Cat#: AXI-1114547
Fetal Calve Serum (FCS) Life Technologies NV Cat#: 10270106
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Perchloric acid Sigma-Aldrich Cat#: 244252-1L
Formaldehyde (16%) Thermo Scientific Cat#: 28906
Protease Inhibitor Cocktail Sigma-Aldrich Cat#: P8465
Dynabeads protein A Invitrogen Cat#: 10002D
Dynabeads protein G Invitrogen Cat#: 10004D
BSA Sigma-Aldrich Cat#: A7030
Tagment DNA buffer Nextera Cat#: 20034197
AMPureXP beads Beckman Coulter Cat#: A63880
KAPA HiFi Hotstart Ready Mix KAPA Biosystems Cat#: KK2601
Nextera DNA Library Prep Kit Illumina Cat#: FC-121-1031
KAPA Library Preparation Kit KAPA Biosystems Cat#: KK8400
TMB (ELISPOT substrate) Mabtech Cat#: 3651-10
Critical commercial assays
CD14 microbeads Milteny Biotec Cat#: 130-091-097
Custom NHP Legendplex (11-plex) Biolegend Cat#: 92919
Monkey IFN-g ELISPOT U-CyTech Cat#: CT610-10
Lactate-ELISA Promokine Cat#: PK-CA577-K627
Deposited data
ChIP sequencing data before and after
BCGiv vaccination
This paper GEO: GSE159046
Experimental models: organism/strain
Rhesus monkeys (Indian); male and female;
adult (> 4 years); purpose bred
BPRC breeding colony not applicable
Software and algorithms
Eli.Analyze (ELISPOT; v6.1) A.EL.VIS GmbH not applicable
FACSDiva Software v 8.0.1 (BD LSRII) BD Biosciences SCR_001456
Flowjo software v 10 Treestar SCR_000410
LEGENDplexTM Data Analysis Software (V8.0) Biolegend/Vigene Tech not applicable





Further information and requests for resources and reagents should be directed to andwill be fulfilled by the Lead Contact Michel PM
Vierboom (vierboom@bprc.nl).
Materials availability
This study did not generate new unique reagents.
Data and code availability
Raw data files of the ChIPseq analysis on BCG trained monocytes begore and after vaccination have been deposited in the NCBI
Gene Expression Omnibus under accession number GEO: GSE159046.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals and ethics
All animal experiments were in accordance with Dutch Law on animal experimentation, which is in accordance with the EU Directive
2010/63/EU on the protection of animals used for scientific purposes. The study was approved by the institutional animal
welfare body (in Dutch: Instantie voor Dierwelzijn, IvD; accession number CCD009D) of BPRC. A cohort of 8 nonvaccinated
control animals was used for Figure S4C. The study in which these animals were used was approved by the institutional animale2 Cell Reports Medicine 2, 100185, January 19, 2021
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OPEN ACCESSwelfare body (Accession number CCD009F). The BPRC is accredited by the American Association for Accreditation of Laboratory
Animal Care (AAALAC) and has an approved Assurance (#A5509-1) for the care and use of animals on file at the National Institutes
of Health (NIH).
The rhesusmonkeys were housed in socially compatible pairs at the Biomedical Primate Research Centre (BPRC; animal biosafety
level ABSL-3). The animals were offered a daily diet consisting of monkey food pellets (Hope Farms, Woerden, the Netherlands), fruit
and vegetables of the season, and bread. Drinking water was available ad libitum via automatic water systems.
The study was carried out in 27 healthy purpose-bred, pedigreed, male and female rhesus monkeys (Macaca mulatta) of Indian
origin (5.99 – 13,50 kg; see Table S1). All animals were screened to be negative for pre-existing immunity against mycobacterial an-
tigens as determined by interferon gamma (IFN-g) ELISpot assay after in vitro recall stimulation with Purified Protein Derivate (PPD) of
M.tuberculosis, M.avium and M.bovis.
All animal handling and biosampling was performed under ketamine sedation (10 mg kg1, by intramuscular injection). For bron-
choalveolar lavage (BAL) and intrabronchial vaccination inoculation with BCG or MTBVAC ketamine (5 mg kg1) was supplemented
with intramuscular medetomidine (0.04 mg kg1) and an analgesic sprayed into the larynx.
Vaccines and vaccination
BCG standard dose & MTBVAC standard dose. Animals immunized with Bacillus Calmette–Guerin (BCG) strain Sofia (InterVax Ltd.)
received a single standard adult human dose of 53 105 CFU. Animals immunized with MTBVAC received an equivalent human dose
of 5 3 105 CFU. Vaccines were delivered in a volume of 0.1 mL intradermally and 10 mL intravenously or intrabronchially. Mucosal
vaccination in the lung was performed by intrabronchial delivery of the same dose in 10mL of sterile saline solution to a segmental
bronchus in the lower right lung lobe using a bronchoscope. Vaccination was executed for all animals in a single session in random
order within 2-3 hours from vaccine preparation
METHOD DETAILS
Biological sample collection and processing
Cells from the pulmonary mucosa were recovered by BAL at week 1 for all groups from the lower right lung lobe; at week 2 after
intravenous BCG and week 8 after intradermal BCG from lower right lung lobe and week 8 after mucosal vaccination from both the
lower right and left lung lobe. Three volumes of 20mL of prewarmed 0.9% saline solution were consecutively instilled and recovered.
BAL fluid was harvested by centrifugation of BAL samples for 10 min at 400 g after 100 mm filtration. Supernatant was subsequently
decanted and stored at 80C pending further analysis. The BAL cell pellet was taken up in Roswell Park Memorial Institute (RPMI)
medium supplemented with 10% FCS, glutaMAX, and penicillin/streptomycin (from now on referred to as R10) and used freshly in
downstream assays. Heparinized blood for immune monitoring, was collected by venipuncture. Bone marrow was obtained through
needle extraction of the caput humerus. PBMCs and BM cells were obtained by density gradient centrifugation with Lymphoprep
lymphocyte separation medium (Axis-Shield) and resuspended in R10 for further analysis.
Mycobacterium uptake and killing assay
To assess mycobacterium uptake, PBMC.mo (30.000 cells/well) were incubated for 1h at 37C with Mtb Erdmann at a MOI of 5.
Non-phagocytosed mycobacterium was washed away and monocytes were incubated with high dose (30 mg/mL) gentamycin for
10-minutes. PBMC.mo were subsequently lysed with 0.05% SDS in water, titrated and plated on to 7H10 agar for bacterial enumer-
ation. To asses killing, PBMC.mo were incubated withMtb Erdmann at a MOI of 5 for 1h at 37C and subsequently cultured with low
gentamycin (5 mg/mL) for 24 hr. Bacteria were enumerated as described before. As a control, bacteria were incubated without
PBMC.mo. Data are presented as % of control (Figure S5).
Monocyte isolation
CD14+ cells (monocytes) were labeled with magnetic CD14 MicroBeads. The cell suspension was loaded onto a MACS Column
which is placed in the magnetic field of a MACS Separator. The magnetically labeled CD14+ cells are retained in the column. The
unlabeled cells run through, this cell fraction is depleted of CD14+ cells. After removal of the column from the magnetic field, the
magnetically retained CD14+ cells can be eluted as the positively selected cell fraction. Purity was analyzed by flowcytometry
(Figure S1).
IFN-g ELISPOT
A NHP specific IFN-g ELISpot assay was used on PBMC, according to the manufacturer protocol (U-CyTech, Utrecht), to determine
the frequency of antigen specific IFN-g producing cells. In brief, 200.000 freshly isolated PBMC were incubated in triplicate for 24 h
with specified antigens or control stimuli. Subsequently, supernatant was collected and stored (80C), and cells were transferred to
specific anti-IFN-g coated filter plates (PVDF, Millipore) for an additional overnight (18 h) incubation. Cells were discarded and
membrane bound IFN-g was detected using biotinylated anti-IFN-g antibody, streptavidin-horseradish peroxidase conjugateCell Reports Medicine 2, 100185, January 19, 2021 e3
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(AELVIS, Hannover).
Flow cytometry
Antigen-specific T cell responses were determined at WK-1 (PRE) and week 8 indicated time points by flow cytometry locally using
BAL cells. Cells were stimulated overnight in the presence of Golgiplug transport inhibitor. The following mAb staining T cell panel
was used: Intracellular staining: CD3 AF700 (SP34-2; BD), TNF-aPE-CY7 (Mab11; BD), IL-2BV510 (MQ1-17H12; BioLegend), IFN-gAPC
(4S.B3; BD); IL-17APE-Cy7 (ebio64DEC17; Thermofisher). Surface staining: CD4PerCP-Cy5.5 (L200; BD), CD8aAPC-H7 (SK1; BD),
CD14BV421 (M5E2; BD), CD20BV421 (2H7; BioLegend), CD45BV786 (D058-1283; BD).
Gating strategy for T cells (Figure S7; Related to Figure 2D)
T cells were gated as Singlets/Lymphocytes/Viable/ CD14-CD20-/CD45+ /CD3+ before CD4 and CD8 gating was applied. After
doublet exclusion, lymphocytes were gated based on size and granularity. Any anomaly indicative of unstable signal acquisition
was excluded using the time parameter. Events from the combined time-gates were plotted against the dump channel containing
the viability, CD14 and C20 markers and subsequently gated as viable, CD14- and CD20-. Cells were further selected for CD45
and CD3 positivity before CD4 and CD8 gating was applied. Boolean gating of any cytokine expression of IL-2/IFN-g/TNFa/IL-17A.
BAL cell composition analysis
Cells were stimulated overnight with WCL. The following mAb staining panel was used to analyze BAL cell composition: CD45AF700
(D058-1283; BD); CD66PE (TET2; Miltenyi); CD206PerCP (15-2;Biolegend); CD16PE-CY7 (3G8; BD); CD3 BV421 (SP34-2;BD); CD20BV605
(2H7; Biolegend); CD14BV786 (M5E2; BD).
Gating strategy for BAL cell composition (Figure S2B)
Singlets/ Leucocytes (CD45)/Viable/Time gate: CD206+/CD14+ (Alveolar Macrophages); CD3 (T cells); CD20 (B cells); CD16+
(NK-cells) and CD66+ (Neutrophils). BAL cell composition is expressed as % from the CD45+/viable fraction.
Isolation of CD14+ monocytes
PBMC or BM cells were incubated with CD14magnetically labeled Microbeads (Miltenyi Biotec; Netherlands). The cell suspension is
loaded onto aMACSColumn which is placed in the magnetic field of a MACS Separator. The magnetically labeled CD14+ cells are
retained in the column. The column is washed once. The column was removed from the magnetic field and the magnetically retained
CD14+ cells were then eluted as the positively selected cell fraction. Purity of CD14+ fraction was subsequently tested by flow
cytometry.
Gating strategy for CD14+ monocytes (Figure S1B)
Singlets/CD45+/ Viable/CD14+. CD14+ cells are expressed as % from the CD45+/viable fraction.
Multiplex cytokine assay
Cells from different sources (PBMC.mo, BM.mo and BAL were stimulated with WCL and titrated amount of LPS (E.coli; Ultrapure).
Freshly isolated cells 25000 cells were incubated ex-vivo for 24 hr with each stimulus after which the supernatant was collected.
Medium alone was taken along for control. Cytokine production was assessed with multi-analyte flow assay kit using a custom
nonhuman primate LegendplexTM (Biolegend; USA). Assays were performed according to the manufacturer’s instructions. Briefly,
the supernatants of stimulated cells were incubated with beads coated with cytokine-specific antibodies. Bound cytokines were
visualized using biotin-coupled detection antibodies and R-phycoerythrin-conjugated streptavidin. Beads were acquired on 3 laser,
14 color LSR-II flow cytometer (BD Biosciences). A NHP custommade 11-plex consisted of TNF-a, IL-6, IL-1b characterizing trained
immunity, GM-CSF, CCL3 (MIP-1a), CXCL10 (IP-10) and cytokines associated with adaptive immunity IFN-g, IL-2, IL-17A.
Lactate measurements
Supernatant collected from the 24 h innate stimulation was analyzed for the production of lactate as a surrogate marker for the meta-
bolic rewiring (Warburg-effect) underlying trained immunity. Proteins in the supernatant, interfering with the lactate analysis, were
denatured precipitated with percholoric acid (PCA) and removed by high speed centrifugation. The clear deproteinized supernatant
was collected and neutralized with NaOH.
Samples were subsequently diluted 15-fold and analyzed in a L-Lactate Assay Kit I (Promokine; PromoCell GmbH; Germany) ac-
cording to manufacturer’s instruction.
Chromatin immunoprecipitation
Cell pellets were dissolved in PBS and crosslinked in solution by using formaldehyde (1% final volume, shaking 10 min at room
temperature). Glycine (0.125 M) was added to quench the reaction. Cells were then washed two times with cold PBS. Cell pellets
were lysed in a volume of 110ml using lysis buffer (20 mM HEPES pH 7.6, 1% SDS, 1 3 Protease Inhibitor Cocktails). Samplese4 Cell Reports Medicine 2, 100185, January 19, 2021
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16,000 3 g for 5 min at room temperature and the supernatant was stored at 80C.
Chromatin from 100,000 cells was used for ChIPmentation. ChIPmentation was performed as described by Schmidl et al.,46 with
several modifications. In short, the chromatin was incubated overnight at 4C rotating in dilution buffer (1% Triton X-100, 1.2 mM
EDTA, 16.7 mM Tris pH 8, 167 mM NaCl), 13 Protease Inhibitor Cocktail47 and 1mg of antibody [H3K27ac (C15410196, Diagenode)]
in a total volume of 300 ml. The next day per ChIP 10ml protein A Dynabeads and 10ml protein G Dynabeads (both Invitrogen) were
added. Beads were washed before use with dilution buffer (+0.15% SDS, +0.1% BSA) and incubated with the chromatin and
antibody mix for 60 min at 4C rotating. Afterward, the beads were washed at 4C once with ChIP wash buffer 1 (2 mM EDTA,
20 mM Tris pH 8, 1%Triton X-100, 0.1% SDS, 150 mMNaCl), twice with ChIP washbuffer 2 (2 mM EDTA, 20 mM Tris pH 8, 1% Triton
X-100, 0.1%SDS, 500 mM NaCl), and twice with TE (1 mM EDTA, 10 mM TrispH 8). Beads were resuspended in 24 ml Tagment DNA
buffer (Nextera) and 1ml Tn5 enzyme (produced in-house) and incubated for 10 min at 37C with 550 rpm shaking. Afterward, the
beads were washed twice with WBI (20 mM HEPES, 150 mM NaCl, 0.1% SDS, 0.1% DOC,1% Triton X-100, 1 mM EDTA,
0.5 mM EGTA) and twice with WBIV (20 mM HEPES, 1 mM EDTA, 0.5 mM EGTA) with 5 min rotating at room temperature in
between. Samples were decrosslinked for 1 h at 55C 1,000 rpm shaking followed by an overnight incubation at 65C using elution
buffer (0.5% SDS, 300 mM NaCl,5 mM EDTA, 10 mM Tris pH 8) and proteinase K. Samples were incubated one additional hour the
next day with elution buffer and proteinase K for 1 h at 55C. The samples were purified using 23 SPRI AMPureXP beads. qPCRwas
used to determine the sufficient amount of PCR cycles needed to amplify the library. The libraries were amplified using the KAPA
HiFi Hotstart Ready Mix (KAPA Biosystems) and Nextera Index Kit 1 (i7) and 2 (i5) primers (Illumina). Amplified libraries were
purified using a 0.65 3 SPRI AMPureXP beads incubation followed by a 1.8 3 SPRI AMPureXP beads incubation. Library
concentration was measured using the KAPA Library Quantification Kit (KAPA Biosystems); library size was determined using the
BioAnalyzer High Sensitivity DNAKit (Agilent). Sequencing was performed using an Illumina HiSeq 2000, and 50-bp paired-end reads
were generated.
ChIP-seq analysis
Sequenced reads were quality and adaptor trimmed with trim galore and cutadapt (Krueger, Felix, Trim galore. ‘‘A wrapper tool
around Cutadapt and FastQC to consistently apply quality and adapter trimming to FastQ files 516 (2015): 517. ‘‘Picard Toolkit.’’
2020. Broad Institute, GitHub; Marin, Marcel. Cutadapt removes adaptor sequences from high-throughput sequencing reads.
EMBnet.journal). These reads were aligned against the UCSC Rhesus reference genome (RheMac10) with Burrows-Wheeler
Aligner (BWA) program48 with default parameters. Duplicate reads were removed with picard MarkDuplicates. Peaks were called
with MACS2 and default settings49 and used to detect the binding sites for ChIP-seq tracks. Tags within a given region were
counted and adjusted to represent the number of tags within a 1 kb region. Subsequently the percentage of these tags as a mea-
sure of the total number of sequenced tags of the sample was calculated and displayed as heatmaps using fluff.50 To determine
genomic locations of binding sites, the peak file was analyzed using a script that annotates binding sites according to all RefSeq
genes.
Necropsy and post-mortem evaluation
Rhesus monkeys were scheduled by protocol for euthanasia and necropsy at 2 weeks (3 animals for BCGIV) or 8 weeks (BCGID,
BCGMUC, MTBVACID, MTBVACMUC) after vaccination. At the end of the experiment blood (< 45 ml) and bone marrow was collected
before euthanasia with sodium pentobarbital (> 50 mg/kg). Samples were stored at 80C for analysis at later time point.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data handling of measurements of cytokine production by Multiplex
The LegendplexTM is a bead-based assay for flow cytometry allowing for the measurement of multiple cytokines in the same sam-
ple. Bead count per analyte was ± 300/sample. Data obtained with a bead count arbitrarily set at < 25 was excluded. Standard
curve (pg/mL) taken along on each plate: 10000, 2500, 625, 156, 39.1, 9.8, 2.4 pg/mL. PRE and WK2/WK8 samples from individual
animals were measured on the same plate to avoid inter-plate variation. Samples from animals from different treatment groups
were randomly distributed over plates. If lower limit of quantification (LLOQ) was < 2.4 pg/mL, the lowest detectable concentration
was set at 2.4 pg/mL. If LLOQ was > 2.4 pg/mL, the lowest detectable concentration was set at LLOQ. This data procedure
ensured a conservative estimation of the fold change between PRE and WK2/WK8 post vaccination.
Statistics comparing routes of vaccination, cytokine, and lactate production
Statistical parameters including number of animals, percentage of cells levels of cytokine production, fold increase of cytokine
production and absolute increase in lactate production are reported in the Figures and Figure legends. Data was analyzed
by ANOVA adjusted for multiple comparisons, Wilcoxon’s non-parametric paired analysis test, Wilcoxon signed rank test to
where applicable. Statistical analyses were conducted using GraphPad Prism 7 software (version 7.0d; GraphPad Software,




Peaks were called with MACS2 and default settings49 and used to detect the binding sites for ChIP-seq tracks. All peaks
were merged using bedtools and for each sample tags per peak were counted. Differential peaks were called by comparing
the two sets of samples using these criteria: the sum of counted tags within one peak using all samples should be > 200 and
the fold difference should be > median plus 2xSD. The testing for gene set/pathway enrichments was done using Fisher’s exact
testing.e6 Cell Reports Medicine 2, 100185, January 19, 2021
